Invivoscribe, a global leader in precision diagnostics, is pleased to announce the successful listings of the LeukoStrat CDx FLT3 Mutation Assay in both the United Kingdom (UK) and Switzerland.
Along with quizartinib, Daiichi Sankyo’s late-stage pipeline projects in cancer are CSF-1R/KIT/FLT3 inhibitor pexidartinib for tenosynovial giant cell tumours and Amgen-partnered anti-RANKL ...
Invivoscribe Announces Registration of the LeukoStrat® CDx FLT3 Mutation Assay in the United Kingdom and Switzerland ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback